REPAIR IMPACT FUND - Key Persons
Camilla Hansen joined Novo Seeds in June of 2018.
Camilla brings 10 years of business development experience from early academic start-up to industry. Most recently, Camilla was responsible for scouting and building new growth platforms for Novozymes A/S. Prior to that, Camilla held a business development position at Statens Serum Institute (SSI) where she was commercializing preclinical and clinical life science products and projects, in addition to being instrumental in divesting the Vaccine Production business from SSI.
From 2009 to 2012 she worked in technology transfer at Wake Forest University Health Sciences in the US where she was involved in out licensing and commercializing early and mid-stage assets, including company creation.
Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.
Emmanuelle Coutanceau joined Novo A/S in September 2015 as Investment Director of Novo Seeds. She led the Series B investments in Corwave, and serves on the Boards of Adenium Biotech, Antag Therapeutics, Avilex Pharma, Corwave, Inthera Bioscience, MinervaX and Pcovery.
Emmanuelle Coutanceau has close to 10 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle Coutanceau was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands.
Emmanuelle Coutanceau obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP.
Søren Møller joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds.
Søren Møller obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren Møller has academic training as postdoctoral fellow at Stanford University School of Medicine.
Prior to joining Novo Seeds, Søren Møller served as global manager of Genomics at Novozymes. Before Novozymes, Søren Møller was CSO and Vice President of R&D at Exiqon A/S. During Søren Møller's tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren Møller worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.
Søren Møller serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren Møller has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).